Profile
ATNX ZTS TAK HLN TEVA NBIX
Company Name Athenex, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $2.33M $67.90B $47.69B $43.90B $22.86B $14.30B
Employees 0.27K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Yiu-Nam Lau F.R.C.P., Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
ATNX ZTS TAK HLN TEVA NBIX
Quant Rating Score 3 3 3 3 1 4
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Buy
Trading
ATNX ZTS TAK HLN TEVA NBIX
Last Close $0.2031 $148.2 $15.1 $9.81 $19.93 $141.87
High 52 $0.2 $196.48 $15.52 $11.41 $22.77 $153.29
Low 52 $0.2 $144.45 $12.89 $9.01 $12.82 $87.59
Price vs. 52 Week High 1.55 % -24.57 % -2.71 % -14.02 % -12.47 % -7.45 %
Price vs. 52 Week Low 1.55 % 2.6 % 17.15 % 8.88 % 55.46 % 61.97 %
Total Return
ATNX ZTS TAK HLN TEVA NBIX
1 Month Return 0 % -3.83 % 0.67 % 1.66 % 11.59 % 6.75 %
3 Month Return 0 % -9.82 % -0.66 % -9.75 % 17.3 % 14.05 %
6 Month Return 0 % -8.1 % 0.6 % -3.35 % 22.05 % 28.1 %
9 Month Return 0 % -16.83 % 12.52 % 0.51 % 20.79 % 11.97 %
YTD Return 0 % -9.04 % 14.05 % 2.83 % -9.57 % 3.93 %
1 Year Return 0 % -22.44 % 2.72 % -6.66 % 8.26 % 16.05 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ATNX ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.26 % 4.36 % 0.02 % - -
Dividend Paid and Capex Coverage Ration (TTM) -36.41 % 1.89 % 2.03 % - 2.78 % 14.7 %
Dividend Per Share (TTM) - 1.93 % 196 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % - - -
Profitability
ATNX ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 25.97 % 70.03 % 60.54 % 61.52 % 49.6 % 98.49 %
Return on Assets TTM -48.5 % 18.04 % 0.98 % 4.2 % -0.39 % 8.95 %
Return on Equity TTM 21.51 % 53.21 % 1.95 % 8.74 % -2.58 % 13.22 %
Return on Capital Employed TTM -78.42 % 31.67 % 3.43 % 7.74 % 3.16 % 14.8 %
Net Income Per EBT TTM 100.35 % 78.72 % 72.1 % 75.5 % 222.54 % 66.08 %
EBT Per Ebit TTM 141.03 % 94.26 % 46.84 % 86.58 % -7.94 % 106.48 %
EBIT Per Revenue TTM -68.02 % 37.51 % 9.05 % 19.64 % 5.38 % 19.72 %
Cash Flow To Debt Ratio TTM -177.1 % 43.13 % 23.79 % - 7.93 % 129.2 %
Receivables Turnover TTM 3.69 6.09 6.59 5.9 4.67 4.21
Payables Turnover TTM 2.26 5.54 4.53 2.19 3.35 0.36
Inventory Turnover TTM 1.78 1.15 1.54 3.63 2.4 0.66
Fixed Asset Turnover TTM 1701.49 % 244.46 % 229.02 % 584.75 % 321.73 % 429.78 %
Asset Turnover TTM 50.39 % 64.82 % 31.99 % 32.73 % 41.43 % 64.53 %
Operating Cash Flow Per Share TTM -11.47 6.58 684.97 - 1.21 5.73
Free Cash Flow Per Share TTM -11.78 4.99 531.34 - 0.78 5.34
Cash Per Share TTM 560.93 % 322.4 % 26788.97 % 24.05 % 188.4 % 985.45 %
Operating Cash Flow Sales Ratio TTM -72.96 % 31.21 % 23.92 % - 8.36 % 22.6 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.75 % 75.76 % 77.57 % - 64.03 % 93.2 %
Cash Flow Coverage Ratios TTM -177.1 % 43.13 % 23.79 % - 7.93 % 129.2 %
Price To Free Cash Flows Ratio TTM -0.03 30.6 8.44 - 25.45 27.05
Price To Operating Cash Flows Ratio TTM -0.02 23.28 6.56 - 16.3 25.16
Price Cash Flow Ratio TTM -0.02 23.28 6.56 - 16.3 25.16
Income Statement (TTM)
ATNX ZTS TAK HLN TEVA NBIX
Revenue $0.1B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0.03B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 25.97% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0.07B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0.1B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -15.13 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
ATNX ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $5.39B $4517.23B $8.54B $16.3B $0.46B
Total Liabilities $0.2B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $-0.02B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0B $10.8B $0.08B $0B $1.71B
Total Debt $0.04B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0.2B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
ATNX ZTS TAK HLN TEVA NBIX
Net Income $-0.1B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $-0.02B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0.08B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $-0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.001
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 3.37
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 8.1
ALVOW Alvotech 1.051
AMPH Amphastar Pharmaceuticals, Inc. 27.72
AMRX Amneal Pharmaceuticals, Inc. 9.845
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 97.81
APUS Apimeds Pharmaceuticals US, Inc 2.05
AQST Aquestive Therapeutics, Inc. 5.155
ASRT Assertio Holdings, Inc. 0.8008
AVDL Avadel Pharmaceuticals plc 15.18
AYTU Aytu BioPharma, Inc. 2.31
ETFs With Exposure to ATNX
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0 140.589
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 144.67
BIB ProShares Ultra Nasdaq Biotechnology 0 56.31
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
DFAU Dimensional US Core Equity Market ETF 0 45.445
IBBQ Invesco Nasdaq Biotechnology ETF 0 23.66
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0 6.8775
VEXPX Vanguard Explorer Fd 0 120.5
JKK iShares Morningstar Small-Cap Growth ETF 0.01 307.42
JKJ iShares Morningstar Small-Cap ETF 0 231.193
Unlock